Diabetes research and clinical practiceNov 2, 2025

Impact of Diabetes Medications on Leg Complications in Peripheral Artery Disease

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 1, 2026

Abstract

GLP-1 receptor agonists (GLP-1RAs) were associated with a 79% reduced risk of major amputation compared to sodium-glucose cotransporter-2 inhibitors (SGLT2i).

GLP-1RAs showed a 18% lower risk of lower extremity revascularization compared to SGLT2i.
All-cause mortality was 29% lower in patients using GLP-1RAs compared to those on SGLT2i.
Similar reductions in risks were observed for GLP-1RAs compared to dipeptidyl peptidase-4 inhibitors (DPP-4i).
SGLT2is and DPP-4is presented comparable risks for major amputation and mortality.
Benefits of GLP-1RAs were consistent in patients with symptomatic peripheral artery disease (PAD).
Semaglutide and tirzepatide were associated with the greatest benefits among GLP-1RAs.

Simplified

AIMS: To compare the association of glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and dipeptidyl peptidase-4 inhibitors (DPP-4i) therapies on lower extremity vascular complications and mortality in PAD.

METHODS: We conducted a retrospective cohort study using a nationwide U.S. electronic health records database. Adults with PAD and type 2 diabetes who initiated GLP-1RA, SGLT2i, or DPP4i therapy (May 2013-January 2025) were included. Propensity score matching (1:1) balanced baseline characteristics. Cox models estimated hazard ratios (HR) with 95 % confidence intervals (CI) for major amputation (primary outcome), lower extremity revascularization (LER), and all-cause mortality over 3 years follow-up. Subgroup analyses included symptomatic PAD, prior LER, and drug-level comparisons.

RESULTS: GLP-1RAs were associated with lower risks of major amputation (HR 0.79 [95 % CI 0.70-0.90]), LER (HR 0.82 [0.76-0.88]), and mortality (HR 0.71 [0.68-0.73]) compared with SGLT2i (n = 77,393 each). Similar reductions were seen versus DPP-4is (n = 39,907 each); SGLT2is and DPP-4is showed comparable risks (n = 42,924 each). GLP-1RA benefits remained significant in symptomatic PAD (p < 0.05) and were associated with lower mortality in LER patients (p < 0.05). Semaglutide and tirzepatide showed the greatest benefit.

CONCLUSION: GLP-1RAs were associated with lower limb complication and mortality risks in PAD, supporting a potential vascular benefit that warrants prospective evaluation.

Full Text

Full text is available at the source.

View Full Text ↗

Impact of Diabetes Medications on Leg Complications in Peripheral Artery Disease

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief